Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936000 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4936008 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5220060 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5220077 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5220068 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5221229 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL14068812 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4936013 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5221240 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4932640 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | SMN1; SMN2 2785/4885NPC1 544/4885RAB9A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.